BALTIMORE, MD--(Marketwired - Jul 15, 2013) - In a newly released research update, Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that the recent Nuvilex, Inc. (OTCQB: NVLX) cancer treatment platform acquisition takes the Company to a new level leading up to future clinical trials and potentially 3rd party funding. Nuvilex Inc. is an international firm engaged in utilizing its live-cell encapsulation technology to develop treatments for pancreatic and other cancers along with the development and study of medical marijuana for use in oncology treatment.
Nuvilex owns exclusive worldwide rights to the live-cell encapsulation-based platform technology for any and all cancer types, including a pancreatic cancer treatment that successfully completed Phase II clinical trials. In those trials, this platform, which essentially serves as an existing therapy booster, has been shown to be very effective while resulting in reduced drug toxicity and enhanced patients' quality of life.
In the Goldman Opportunity Research update on the Company, analyst Rob Goldman outlines his investment thesis.
"Nuvilex has obtained the exclusive worldwide rights to the live-cell encapsulation platform technology previously owned by SG Austria's BioBlueBird AG, thus enabling Nuvilex to use it for all cancers. All roads seeking to utilize this technology in all of oncology therapy, not just pancreatic cancer, now go through Nuvilex. The value of the intellectual property for a market in the tens of billions is worth far more than the pittance for which the stock currently trades, considering the clinical trial history. Importantly, the deal was funded via the sale of restricted stock to accredited investors at $0.125 per share, which is a premium (not discount) to the current share price at what we project is a dilutive effect of less than 3%.
That is a huge statement as most deals of this type are priced at a discount. We expect that this transaction will lead to future clinical trials and potentially 3rd party funding as well. Plus, management is not done. Nuvilex plans to build on its oncology treatment flagship along with new treatments for other indications with a great unmet medical need."
To view Nuvilex reports and articles or to download the report in its entirety, please visit
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. has been a provider of all-natural products for many years, has expanded its company to increase its natural product based footprint through medical marijuana studies and is becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine. The Company's offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. For more information visit: www.nuvilex.com.